Bavisant

N/A

Report date: 2024/05/28 20:00:12
NME

Base Information

Drug NameBavisant
Drug Alias Name巴维桑特bavisantumBEN-2001JNJ-1074JNJ-31001074
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistamine H3 receptor antagonists
TargetsHistamine H3 receptor
Therapy Area/IndicationsAttention Deficit Disorder with HyperactivityAlcoholismDisorders of Excessive Somnolence +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBenevolentai Bio LtdJanssen Research & Development LlcJohnson & Johnson Pharmaceutical Research & Development LLC
Active IndicationsN/A
Inactive IndicationsAttention Deficit Disorder with HyperactivityAlcoholismDisorders of Excessive Somnolence +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG